Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin: A Monocentric Interventional Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 63
- Locations
- 2
- Primary Endpoint
- ChARMin-5: Game scores [points]
Study Overview
Brief Summary
The purpose of this study is to investigate the applicability and feasibility of the newly developed robot platform for upper extremity therapy ("ChARMin") in children undergoing neurorehabilitation.
Detailed Description
Background and Rationale: Children with neurological diagnoses including congenital or acquired brain lesions often have impaired upper extremity function that limits activities of daily life and independence. While several rehabilitation technologies in the clinical routines are being applied to improve upper extremity functions in these patients, the technology to train more severely affected children was not available so far. Since 3 years, the investigators are working together with the Sensory-Motor Systems Lab at ETH Zurich on a new robot platform specifically developed for upper extremity therapy in children (the 'Children's Arm Rehabilitation Mechatronic Interface' or 'ChARMin'). This group showed recently in a single blinded RCT that their adult upper extremity robot ARMin is an effective neurorehabilitation tool for adults after stroke (especially for the more severely affected patients). Now, that ChARMin is finished the investigators would like to study whether it is feasible to apply this prototype to children and adolescents undergoing neurorehabilitation.
Objective(s): As ChARMin was specifically developed for children and adolescents, the investigators first want to explore whether it is feasible to apply it to children and adolescents undergoing neurorehabilitation. Six studies will be performed with the following main objectives: (i) to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin; (ii) to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode; (iii) to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin; (iv) to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group); (v) specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions; (vi) to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject iv).
Outcome(s): The outcomes are in line with the objectives of each subproject. Some outcome measures are specifically performed for this study (e.g. safety, game scores, assessments integrated in ChARMin), others are clinically routinely applied measures (no additional burden for the patient). The investigators do not apply any invasive tools and assure that the amount of additional assessments will be limited to keep the burden for the participants acceptable.
Study design: Most projects are open labelled interventional studies investigating the applicability, safety and usability of a newly developed upper extremity robot ChARMin. Project (i) will investigate the feasibility of ChARMin in 30 children and adolescents. Project (ii) will be a randomized study investigating differences in the various measures between the 3 control modes of ChARMin. Project (iii) include psychometric studies where a single measurement is necessary (validity), or two repeated measurements are performed (within 3-7 days to determine reliability and between onset and end of rehabilitation to determine responsiveness). Project (v) consists of motor learning studies where a large number of repetitions are performed in a relative short time to determine changes in task performance, retention and generalizability. Projects (iv) and (vi) are open labelled interventional studies investigating the application of ChARMin and concomitant changes in upper extremity function without control group.
Measurements and procedures: Participants will be positioned in a comfortable position on a chair. After the required anthropometrics have been assessed, the ChARMin is adjusted and the cuffs of ChARMin will be fixated to the patient. Depending on the study, the participant will be informed and instructed what task/assessment or game will be made and what the goal is. Then, the participant will perform the task, while the investigator/therapist will be there to answer any questions, make sure the patient is comfortable, and to control the device, including the emergency buttons. Afterwards, the investigator/therapist will loosen the cuffs and assist if needed the participant getting out of the chair. The therapist will control the participant's skin and will ask for any other signs of discomfort. The duration of a session will remain within 45 minutes. In other sessions, clinical routine assessments will be performed.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 5 Years to 21 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age between 5 and 21 years
- •Neurological diagnoses
- •Impairment of the upper extremity (for projects (i) and (ii) we might also include patients without upper extremity impairments to cover a wide range of patients with different abilities)
- •Other (non-neurological) diagnoses, who require intense training of the upper extremity
Exclusion Criteria
- •Strong adipositas, which makes it not possible to adjust the cuffs and orthoses to the anthropometrics of the participant
- •Fixed contractures of the upper extremity that should be positioned in ChARMin
- •Instabilities of bones or joints, fractures or osteoporosis/osteopenia
- •Allergy against material of cuffs
- •Open skin lesions of the upper extremity that should be positioned in ChARMin
- •Luxations or subluxations of joints of the upper extremity that should be positioned in ChARMin
- •Strong pain that increases while training in ChARMin*
- •Injuries or lesioned nerves of the upper extremity that should be positioned in ChARMin*
- •Strong spontaneous movements like ataxia, dyskinesia, myoclonus*
- •Instable vital functions like pulmonal or cardiovascular conditions
- •Implanted pace maker, defibrillator of the heart
- •Implanted shunt by hydrocephalus*
- •Implanted cochlear or baha*
- •Uncooperative or aggressive behaviour
- •Known or suspected non-compliance
- •Severe cognitive deficits
- •Inability to signal pain or discomfort
- •Apraxia*
- •Severe visual impairment (inability to see the screen)
- •Severe spasticity (Ashworth 4)
- •Severe epilepsy*
- •Insufficient head stability
- •Infections requiring isolation of the patient Contraindications marked with an * are relative contraindications. Final approval needs to be obtained from the medical doctor.
Arms & Interventions
ChARMin
Single-arm only
Intervention: ChARMin (Device)
Outcomes
Primary Outcomes
ChARMin-5: Game scores [points]
Time Frame: up to 24 weeks
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software
Time Frame: At onset and end of the hospital stay, which covers an expected average of 7 weeks
To assess the responsiveness of the assessment battery. The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
ChARMin-1: Score on the feasibility questionnaire [points]
Time Frame: Up to 8 weeks
The feasibility questionnaire is a self-developed tool, which covers the following areas: * Technical aspects: * Patient-related aspects: * Safety * Interface/Games/Assessments
ChARMin-2: Game Scores [points]
Time Frame: up to 24 weeks
To calculate the game scores of each game, several kinematic and kinetic measures are recorded and processed during the games (for instance number of collected items)
ChARMin-3: Assessment battery integrated into the ChARMin software [points]
Time Frame: Up to 24 weeks
The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
ChARMin-4 and ChARMin-6: Change from baseline in the Box and Block Test [delta of the number of blocks transferred]
Time Frame: At onset and end of hospital stay, which covers an expected average of 7 weeks
Individuals are seated at a table, facing a rectangular box that is divided into two square compartments of equal dimension by means of a partition. 150, 2.5 cm, colored, wooden cubes or blocks are placed in one compartment or the other. The participant is instructed to move as many blocks as possible, one at a time, from one compartment to the other for a period of 60 seconds. To administer the test, the examiner is seated opposite the individual in order to observe test performance. The BBT is scored by counting the number of blocks carried over the partition from one compartment to the other during the one-minute trial period. Patient's hand must cross over the partition in order for a point to be given, and blocks that drop or bounce out of the second compartment onto the floor are still rewarded with a point.
ChARMin-3: Change from baseline of the assessment battery integrated into the ChARMin software [delta points]
Time Frame: Twice within 3-7 days
To assess the reliability of the assessment battery. The assessment battery consists of: * Range of motion * Workspace measurement * Quality of movement during targeted movements * Isometric strength measurement * Resistance to passive movement of the arm (stiffness) * Accuracy of performing a circle movement in the frontal plane.
Secondary Outcomes
- ChARMin-2: Force measures provided by ChARMin [Newton](up to 24 weeks)
- ChARMin-2: Adverse events [number and kind of events](up to 24 weeks)
- ChARMin-2: Palmar skin conductance [microVolt](up to 24 weeks)
- ChARMin-2: Amplitude of muscle activation [microVolt](up to 24 weeks)
- ChARMin-2: Score on the motivational questionnaire [points](up to 24 weeks)
- ChARMin-2: Joint angle measures provided by ChARMin [degrees](up to 24 weeks)
- ChARMin-2: Heart rate [beats per minute](up to 24 weeks)
- ChARMin-4 and ChARMin-6: Change from baseline in the score of the assessment battery integrated into the ChARMin software [delta points](At onset and end of hospital stay, which covers an expected average of 7 weeks)
- ChARMin-4 and ChARMin-6: Change from baseline in strength of fingers and hand [delta Newton](At onset and end of hospital stay, which covers an expected average of 7 weeks)
- ChARMin-4 and ChARMin-6: Change from baseline in the Nine-hole Peg Test [delta seconds](At onset and end of hospital stay, which covers an expected average of 7 weeks)
- ChARMin-4 and ChARMin-6: Change from baseline in the brain reorganization measured by transcranial magnetic stimulation [delta milliseconds](At onset and end of hospital stay, which covers an expected average of 7 weeks)
Investigators
Huub van Hedel
Head of Research and Therapies Rehabilitation Center for Children and Adolescents
University Children's Hospital, Zurich
